Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
François Cherifi, Angélique Da Silva, Diogo Martins-Branco, Ahmad Awada & Guilherme Nader-Marta. (2024) Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer. Expert Opinion on Drug Metabolism & Toxicology 20:1-2, pages 45-59.
Read now
Read now
Anna R. Schreiber, Cindy L. O’Bryant, Peter Kabos & Jennifer R. Diamond. (2023) The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan. Expert Review of Anticancer Therapy 23:10, pages 1061-1069.
Read now
Read now
Nadia Saoudi Gonzalez, Daniel López, Diego Gómez, Javier Ros, Iosune Baraibar, Francesc Salva, Josep Tabernero & Elena Élez. (2022) Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. Expert Opinion on Drug Metabolism & Toxicology 18:11, pages 755-767.
Read now
Read now
Jiyun Lee & Yeon Hee Park. (2022) Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer. Future Oncology 18:1, pages 7-19.
Read now
Read now
Ibrahim Azar, Samer Alkassis, Jami Fukui, Fares Alsawah, Kalub Fedak, Mohammed Najeeb Al Hallak, Ammar Sukari & Misako Nagasaka. (2021) Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer: Targets and Therapy 12, pages 103-114.
Read now
Read now
Takahiro Ishii & Kohei Shitara. (2021) Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer. Expert Review of Anticancer Therapy 21:11, pages 1193-1201.
Read now
Read now
Saori Mishima & Kohei Shitara. (2021) Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. Expert Opinion on Biological Therapy 21:7, pages 825-830.
Read now
Read now
Jose Perez, Laia Garrigós, Maria Gion, Pasi A. Jänne, Kohei Shitara, Salvatore Siena & Javier Cortés. (2021) Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. Expert Opinion on Biological Therapy 21:7, pages 811-824.
Read now
Read now
Yutaka Matsuda & Brian A. Mendelsohn. (2021) An overview of process development for antibody-drug conjugates produced by chemical conjugation technology. Expert Opinion on Biological Therapy 21:7, pages 963-975.
Read now
Read now
Hiromi Okamoto, Masataka Oitate, Katsunobu Hagihara, Hideyuki Shiozawa, Yoshitake Furuta, Yusuke Ogitani & Hiroshi Kuga. (2020) Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Xenobiotica 50:10, pages 1242-1250.
Read now
Read now
Rita De Santis. (2020) Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy. mAbs 12:1.
Read now
Read now
Articles from other publishers (49)
Miguel Martín, Atanasio Pandiella, Emilio Vargas-Castrillón, Elena Díaz-Rodríguez, Teresa Iglesias-Hernangómez, Concha Martínez Cano, Inés Fernández-Cuesta, Elena Winkow & Maria Francesca Perelló. (2024) Trastuzumab deruxtecan in breast cancer. Critical Reviews in Oncology/Hematology 198, pages 104355.
Crossref
Crossref
Shunji Takahashi, Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani, Yung-Jue Bang, Yuta Sato, Shunsuke Nakatani, Caleb Lee, Masahiro Sugihara, Yasuyuki Okuda & Hiroji Iwata. (2024) Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies. Japanese Journal of Clinical Oncology 54:4, pages 434-443.
Crossref
Crossref
Rebecca Ibrahim, Rita Khoury, Tony Ibrahim, Axel Le Cesne & Tarek Assi. (2024) UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?. Critical Reviews in Oncology/Hematology 196, pages 104265.
Crossref
Crossref
Hiroaki Yamane, Yoichi Sugiyama, Toshiaki Komo, Kosuke Shibata, Tatsuya Tazaki, Mohei Koyama & Masaru Sasaki. (2024) Long-Term Complete Response to Trastuzumab Deruxtecan in a Case of Unresectable Gastric Cancer. Case Reports in Oncology 17:1, pages 463-470.
Crossref
Crossref
Ling Zhou, Yunlong Lu, Wei Liu, Shanglong Wang, Lingling Wang, Pengdou Zheng, Guisha Zi, Huiguo Liu, Wukun Liu & Shuang Wei. (2024) Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice. Experimental Hematology & Oncology 13:1.
Crossref
Crossref
Meng Li, Xueyu Zhao, Chuanfei Yu & Lan Wang. (2024) Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy. Pharmaceutical Research 41:3, pages 419-440.
Crossref
Crossref
Dan‐Yun Ruan, Hao‐Xiang Wu, Qi Meng & Rui‐Hua Xu. (2023) Development of antibody‐drug conjugates in cancer: Overview and prospects. Cancer Communications 44:1, pages 3-22.
Crossref
Crossref
Gavin P. Dowling, Gordon R. Daly, Stephen Keelan, Fiona Boland, Sinead Toomey, Arnold D.K. Hill & Bryan T. Hennessy. (2023) Efficacy and Safety of Trastuzumab Deruxtecan in Breast Cancer: A Systematic Review and Meta-Analysis. Clinical Breast Cancer 23:8, pages 847-855.e2.
Crossref
Crossref
Blair McNamara, Michelle Greenman, Nicole Pebley, Levent Mutlu & Alessandro D. Santin. (2023) Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors. Molecules 28:21, pages 7389.
Crossref
Crossref
Ritchu Babbar, Vanya, Aarti Bassi, Rashmi Arora, Ankur Aggarwal, Pranay Wal, Sunil Kumar Dwivedi, Salma Alolayan, Monica Gulati, Celia Vargas-De-La-Cruz, Tapan Behl & Shreesh Ojha. (2023) Understanding the promising role of antibody drug conjugates in breast and ovarian cancer. Heliyon 9:11, pages e21425.
Crossref
Crossref
Hiromi Habara, Hiromi Okamoto, Yoko Nagai, Masataka Oitate, Hideo Takakusa & Nobuaki Watanabe. (2023) Transition of average drug‐to‐antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography‐tandem mass spectrometry. Biopharmaceutics & Drug Disposition 44:5, pages 380-384.
Crossref
Crossref
Andrea D’Arienzo, Annarita Verrazzo, Martina Pagliuca, Fabiana Napolitano, Sara Parola, Martina Viggiani, Roberta Caputo, Fabio Puglisi, Mario Giuliano, Lucia Del Mastro, Grazia Arpino, Michelino De Laurentiis & Filippo Montemurro. (2023) Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. eClinicalMedicine 62, pages 102113.
Crossref
Crossref
Kanwal P.S. Raghav & Mark M. Moasser. (2023) Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. Clinical Cancer Research 29:13, pages 2351-2361.
Crossref
Crossref
Miho Nagayasu, Yoko Takano & Kazuhisa Ozeki. (2023) Development of a New Method to Evaluate the Biodistribution of Antibodies Using Non-Radioactive Metal Labeling and Inductively Coupled Plasma Mass Spectrometry. Pharmaceutical Research 40:7, pages 1807-1819.
Crossref
Crossref
Weining Weng, Tao Meng, Qianqian Zhao, Yi Shen, Guoxiang Fu, Jing Shi, Yue Zhang, Zhaohui Wang, Mingqiao Wang, Rong Pan, Linjie Ma, Caiwei Chen, Lijun Wang, Biao Zhou, Hui Zhang, Junyi Pu, Jianjian Zhang, Yi Peter Hu, Guoqiang Hua, Yu Qian, Shu-Hui Liu, Wenhao Hu & Xun Meng. (2023) Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discovery 13:4, pages 950-973.
Crossref
Crossref
Louise Conilh, Lenka Sadilkova, Warren Viricel & Charles Dumontet. (2023) Payload diversification: a key step in the development of antibody–drug conjugates. Journal of Hematology & Oncology 16:1.
Crossref
Crossref
Solène Marie, Kayla L. Frost, Raymond K. Hau, Lucy Martinez-Guerrero, Jailyn M. Izu, Cassandra M. Myers, Stephen H. Wright & Nathan J. Cherrington. (2023) Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. Acta Pharmaceutica Sinica B 13:1, pages 1-28.
Crossref
Crossref
Adrian D. Hobson. 2023.
1
59
.
Yasong Lu, Shinji Shimizu, Ryoko Sawamura, Naoyuki Tajima, Ling He, Mark Lee, Malaz Abutarif & Rong Shi. (2022) Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors. The Journal of Clinical Pharmacology 63:1, pages 77-90.
Crossref
Crossref
Yezhe Cheng, Xiaoxi Yuan, Qiang Tian, Xiuying Huang, Yang Chen, Yuzhi Pu, Hu Long, Mingyu Xu, Yafei Ji, Jia Xie, Yuping Tan, Xi Zhao & Hongmei Song. (2022) Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Frontiers in Oncology 12.
Crossref
Crossref
Xinwei Peng, Jibin Li, Yuwan Wu, Hongji Dai, Henry S. Lynn & Xi Zhang. (2022) Association of Stool Frequency and Consistency with the Risk of All-Cause and Cause-Specific Mortality among U.S. Adults: Results from NHANES 2005–2010. Healthcare 11:1, pages 29.
Crossref
Crossref
Hanyue Xu, Hao Zhang, Wen Guo, Xi Zhong, Jing Sun, Tao Zhang, Zhoufeng Wang & Xuelei Ma. (2022) Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials. BMC Cancer 22:1.
Crossref
Crossref
Iftekhar Mahmood. (2022) A Simple Method for the Prediction of Human Concentration–Time Profiles and Pharmacokinetics of Antibody–Drug Conjugates (ADC) from Rats or Monkeys. Antibodies 11:2, pages 42.
Crossref
Crossref
Hiromichi Nakajima, Kenichi Harano, Tokiko Nakai, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Shuichi Mitsunaga, Genichiro Ishii & Toru Mukohara. (2022) Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer. The Breast 61, pages 136-144.
Crossref
Crossref
Takashi Nakada, Yuki Abe & Toshinori Agatsuma. 2021. Chemical Linkers in Antibody–Drug Conjugates (ADCs). Chemical Linkers in Antibody–Drug Conjugates (ADCs)
422
450
.
Shunji Takahashi, Masato Karayama, Masato Takahashi, Junichiro Watanabe, Hironobu Minami, Noboru Yamamoto, Ichiro Kinoshita, Chia-Chi Lin, Young-Hyuck Im, Issei Achiwa, Emi Kamiyama, Yasuyuki Okuda, Caleb Lee & Yung-Jue Bang. (2021) Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. Clinical Cancer Research 27:21, pages 5771-5780.
Crossref
Crossref
Brian C. Grieb & Rajiv Agarwal. (2021) HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles. Current Treatment Options in Oncology 22:10.
Crossref
Crossref
Diana Lüftner & Matthias Peipp. (2021) Neue Therapiestrategien beim HER2-positiven fortgeschrittenen, inoperablen bzw. metastasierten Mammakarzinom. Senologie - Zeitschrift für Mammadiagnostik und -therapie 18:03, pages 240-253.
Crossref
Crossref
Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara, Yusuke Ogitani, Tadaaki Nishikawa, Mayu Ohuchi, Takashi Teishikata, Takahiro Jikoh, Yasushi Yatabe, Kan Yonemori, Kenji Tamura, Kosei Hasegawa & Akinobu Hamada. (2021) Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. Clinical Cancer Research 27:14, pages 3970-3979.
Crossref
Crossref
Kohei Shitara, Eishi Baba, Kazumasa Fujitani, Eiji Oki, Satoshi Fujii & Kensei Yamaguchi. (2021) Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer 24:4, pages 780-789.
Crossref
Crossref
Diego Salas-Benito, José L. Pérez-Gracia, Mariano Ponz-Sarvisé, María E. Rodriguez-Ruiz, Iván Martínez-Forero, Eduardo Castañón, José M. López-Picazo, Miguel F. Sanmamed & Ignacio Melero. (2021) Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discovery 11:6, pages 1353-1367.
Crossref
Crossref
Diana Lüftner & Matthias Peipp. (2021) New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer. Geburtshilfe und Frauenheilkunde 81:06, pages 666-678.
Crossref
Crossref
Angeliki Andrikopoulou, Eleni Zografos, Michalis Liontos, Konstantinos Koutsoukos, Meletios-Athanasios Dimopoulos & Flora Zagouri. (2021) Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. Clinical Breast Cancer 21:3, pages e212-e219.
Crossref
Crossref
Xiu-Fang Li, Chen-Fu Liu & Guo-Wu Rao. (2021) Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors. Current Medicinal Chemistry 28:17, pages 3339-3360.
Crossref
Crossref
Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler & Felix M. Mottaghy. (2020) HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. European Journal of Nuclear Medicine and Molecular Imaging 48:5, pages 1371-1389.
Crossref
Crossref
Angela Dalia Ricci, Alessandro Rizzo, Fabiola Lorena Rojas Llimpe, Francesca Di Fabio, Dario De Biase & Karim Rihawi. (2021) Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?. Cancers 13:7, pages 1664.
Crossref
Crossref
Louise Conilh, Guy Fournet, Eric Fourmaux, Angélique Murcia, Eva-Laure Matera, Benoît Joseph, Charles Dumontet & Warren Viricel. (2021) Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals 14:3, pages 247.
Crossref
Crossref
Biagio Ricciuti, Giuseppe Lamberti, Elisa Andrini, Carlo Genova, Andrea De Giglio, Vanessa Bianconi, Amirhossein Sahebkar, Rita Chiari & Matteo Pirro. (2021) Antibody–drug conjugates for lung cancer in the era of personalized oncology. Seminars in Cancer Biology 69, pages 268-278.
Crossref
Crossref
Takashi NAKADA. (2021) Discovery research and translation science of trastuzumab deruxtecan, from non-clinical study to clinical trial. Translational and Regulatory Sciences 3:2, pages 65-71.
Crossref
Crossref
Daisuke Kotani & Kohei Shitara. (2021) Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592098651.
Crossref
Crossref
Kazuyoshi Kumagai, Tetsuo Aida, Yoshimi Tsuchiya, Yuki Kishino, Kiyonori Kai & Kazuhiko Mori. (2020) Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2‐targeting Ab–drug conjugate, in monkeys. Cancer Science 111:12, pages 4636-4645.
Crossref
Crossref
Valentina Gambardella, Tania Fleitas, Noelia Tarazona, Federica Papaccio, Marisol Huerta, Susana Roselló, Francisco Gimeno-Valiente, Desamparados Roda & Andrés Cervantes. (2020) Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. Journal of Clinical Medicine 9:9, pages 3049.
Crossref
Crossref
Jeffrey Leyton. (2020) Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2. Antibodies 9:3, pages 32.
Crossref
Crossref
Kohei ShitaraYung-Jue BangSatoru IwasaNaotoshi SugimotoMin-Hee RyuDaisuke SakaiHyun-Cheol ChungHisato KawakamiHiroshi YabusakiJeeyun LeeKaku SaitoYoshinori KawaguchiTakahiro KamioAkihito KojimaMasahiro SugiharaKensei Yamaguchi. (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine 382:25, pages 2419-2430.
Crossref
Crossref
A. Yver, T. Agatsuma & J.-C. Soria. (2020) The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers. Annals of Oncology 31:3, pages 430-434.
Crossref
Crossref
Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Helen Gogas & Dimitrios C. Ziogas. (2020) An overview of antibody–drug conjugates in oncological practice. Therapeutic Advances in Medical Oncology 12, pages 175883592096299.
Crossref
Crossref
Yuuri Hashimoto, Kumiko Koyama, Yasuki Kamai, Kenji Hirotani, Yusuke Ogitani, Akiko Zembutsu, Manabu Abe, Yuki Kaneda, Naoyuki Maeda, Yoshinobu Shiose, Takuma Iguchi, Tomomichi Ishizaka, Tsuyoshi Karibe, Ichiro Hayakawa, Koji Morita, Takashi Nakada, Taisei Nomura, Kenichi Wakita, Takashi Kagari, Yuki Abe, Masato Murakami, Suguru Ueno & Toshinori Agatsuma. (2019) A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization. Clinical Cancer Research 25:23, pages 7151-7161.
Crossref
Crossref
Zhuyu Xu, Dandan Guo, Zhongliang Jiang, Rongsheng Tong, Peidu Jiang, Lan Bai, Lu Chen, Yuxuan Zhu, Chun Guo, Jianyou Shi & Dongke Yu. (2019) Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). European Journal of Medicinal Chemistry 183, pages 111682.
Crossref
Crossref
Wei Li, Karen H. Veale, Qifeng Qiu, Kerstin W. Sinkevicius, Erin K. Maloney, Juliet A. Costoplus, Janet Lau, Helen L. Evans, Yulius Setiady, Olga Ab, Stephen M. Abbott, Jenny Lee, Somsinee Wisitpitthaya, Anna Skaletskaya, Lintao Wang, Thomas A. Keating, Ravi V. J. Chari & Wayne C. Widdison. (2019) Synthesis and Evaluation of Camptothecin Antibody–Drug Conjugates. ACS Medicinal Chemistry Letters 10:10, pages 1386-1392.
Crossref
Crossref